An insider at Compass Pathways plc (NASDAQ:CMPS), a pharmaceutical company specializing in mental health care, has recently sold a significant number of shares. According to the latest SEC filings, the transactions took place on March 28, 2024, involving ordinary shares which may be represented by American Depositary Shares.
The transactions were carried out by George Jay Goldsmith, a significant shareholder of the company, and his spouse, Dr. Ekaterina Malievskaia. Goldsmith sold a total of 25,750 shares at a weighted average price of $8.6515, with sales prices ranging from $8.31 to $9.21. The total value of Goldsmith's sold shares amounted to approximately $445,552. It's important to note that these sales occurred automatically pursuant to a Rule 10b5-1 trading plan that was adopted on August 23, 2023.
Following the transactions, Goldsmith's direct holdings in the company decreased to 4,036,154 shares. Additionally, a similar number of shares were sold indirectly by his spouse, Dr. Malievskaia, who holds securities separately. Despite their marital status, both parties have expressly disclaimed beneficial ownership of each other's shares in Compass Pathways.
The reported transactions provide investors with an insight into the trading activities of Compass Pathways' insiders, which can be a valuable piece of information for those tracking the company's stock performance and insider confidence.
InvestingPro Insights
Amidst the recent insider trading activity at Compass Pathways plc (NASDAQ:CMPS), investors are keen to understand the company's financial health and market performance. Compass Pathways, which has been navigating the challenges of the pharmaceutical industry, holds a market capitalization of $568.61 million. Despite a difficult period, the company maintains a positive liquidity position, with cash reserves outstripping debt on their balance sheet.
InvestingPro data reveals that Compass Pathways has a negative price-to-earnings (P/E) ratio of -3.59, reflecting the company's lack of profitability in the last twelve months as of Q4 2023. This is further emphasized by an adjusted P/E ratio of -4.8 for the same period. The company's stock price has experienced significant volatility, with a one-month total return of -27.53% as of the latest data, highlighting the stock's recent performance struggles.
For investors considering Compass Pathways' future prospects, it's important to note that analysts do not anticipate the company to be profitable this year. Additionally, Compass Pathways does not currently pay a dividend to shareholders, which may influence investment decisions for those seeking income-generating assets. Investors can explore further InvestingPro Tips by visiting https://www.investing.com/pro/CMPS, which currently lists an additional 9 tips for a more comprehensive analysis.
Those interested in deeper insights and analysis can take advantage of a special offer on a yearly or biyearly Pro and Pro+ subscription at InvestingPro. Use the coupon code PRONEWS24 to receive an additional 10% off.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.